{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T09:58:01Z","timestamp":1770976681157,"version":"3.50.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T00:00:00Z","timestamp":1758499200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T00:00:00Z","timestamp":1758499200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Grants and Funding Anhui Provincial Key Research and Development Project","award":["2022e07020057"],"award-info":[{"award-number":["2022e07020057"]}]},{"name":"the Special Project for Clinical Medical Research Transformation of Key Research and Development Projects in Fuyang City","award":["FYZDYF2023LCYX002"],"award-info":[{"award-number":["FYZDYF2023LCYX002"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"DOI":"10.1186\/s12882-025-04458-9","type":"journal-article","created":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T11:04:59Z","timestamp":1758539099000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Identification of a new CD46 gene mutation site in a family with atypical hemolytic uremic syndrome"],"prefix":"10.1186","volume":"26","author":[{"given":"Benjin","family":"Hu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongchuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongdong","family":"Mei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaohua","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaowei","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,22]]},"reference":[{"key":"4458_CR1","first-page":"1722","volume":"400","author":"M Michael","year":"2022","unstructured":"Michael M, Bagga A, Sartain SE, Smith RJH. Haemolytic Uraemic Syndrome Lancet. 2022;400:1722\u201340.","journal-title":"Haemolytic Uraemic Syndrome Lancet"},{"key":"4458_CR2","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/1744-9987.12763","volume":"23","author":"R Raina","year":"2019","unstructured":"Raina R, Krishnappa V, Blaha T, Kann T, Hein W, Burke L, et al. Atypical hemolytic-uremic syndrome: an update on pathophysiology, diagnosis, and treatment. Ther Apher Dial. 2019;23:4\u201321.","journal-title":"Ther Apher Dial"},{"key":"4458_CR3","first-page":"CD012862","volume":"3","author":"D Pugh","year":"2021","unstructured":"Pugh D, O\u2019Sullivan ED, Duthie FA, Masson P, Kavanagh D. Interventions for atypical haemolytic uraemic syndrome. Cochrane Database Syst Rev. 2021;3:CD012862.","journal-title":"Cochrane Database Syst Rev"},{"key":"4458_CR4","doi-asserted-by":"crossref","unstructured":"Goodship TH, Cook HT, Fakhouri F, Fervenza FC, Fr\u00e9meaux-Bacchi V, Kavanagh D et al. Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a kidney disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2017;91:539\u2013551.","DOI":"10.1016\/j.kint.2016.10.005"},{"key":"4458_CR5","doi-asserted-by":"publisher","first-page":"853","DOI":"10.3389\/fimmu.2019.00853","volume":"10","author":"E Valoti","year":"2019","unstructured":"Valoti E, Alberti M, Iatropoulos P, Piras R, Mele C, Breno M, et al. Rare functional variants in complement genes and Anti-FH Autoantibodies-Associated aHUS. Front Immunol. 2019;10:853.","journal-title":"Front Immunol"},{"key":"4458_CR6","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/ng.2590","volume":"45","author":"M Lemaire","year":"2013","unstructured":"Lemaire M, Fr\u00e9meaux-Bacchi V, Schaefer F, Choi M, Tang WH, Le Quintrec M, et al. Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome. Nat Genet. 2013;45:531\u20136.","journal-title":"Nat Genet"},{"key":"4458_CR7","doi-asserted-by":"publisher","first-page":"2809","DOI":"10.1681\/ASN.2018070759","volume":"29","author":"F Bu","year":"2018","unstructured":"Bu F, Zhang Y, Wang K, Borsa NG, Jones MB, Taylor AO, et al. Genetic analysis of 400 patients refines Understanding and implicates a new gene in atypical hemolytic uremic syndrome. J Am Soc Nephrol. 2018;29:2809\u201319.","journal-title":"J Am Soc Nephrol"},{"key":"4458_CR8","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1681\/ASN.2019050515","volume":"31","author":"PF Zipfel","year":"2020","unstructured":"Zipfel PF, Wiech T, Stea ED, Skerka C. CFHR gene variations provide insights in the pathogenesis of the kidney diseases atypical hemolytic uremic syndrome and C3 glomerulopathy. J Am Soc Nephrol. 2020;31:241\u201356.","journal-title":"J Am Soc Nephrol"},{"key":"4458_CR9","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1046\/j.1523-1755.1998.00130.x","volume":"54","author":"M Nangaku","year":"1998","unstructured":"Nangaku M. Complement regulatory proteins in glomerular diseases. Kidney Int. 1998;54:1419\u201328.","journal-title":"Kidney Int"},{"key":"4458_CR10","doi-asserted-by":"crossref","unstructured":"Maga TK, Nishimura CJ, Weaver AE, Frees KL, Smith RJH. Mutations in alternative pathway complement proteins in American patients with atypical hemolytic uremic syndrome. Hum Mutat. 2010;31.","DOI":"10.1002\/humu.21256"},{"key":"4458_CR11","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1093\/ndt\/gfq010","volume":"25","author":"D Westra","year":"2010","unstructured":"Westra D, Volokhina E, van der Heijden E, Vos A, Huigen M, Jansen J, et al. Genetic disorders in complement (regulating) genes in patients with atypical haemolytic uraemic syndrome (aHUS). Nephrol Dial Transpl. 2010;25:2195\u2013202.","journal-title":"Nephrol Dial Transpl"},{"key":"4458_CR12","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.molimm.2006.07.004","volume":"44","author":"A Richards","year":"2007","unstructured":"Richards A, Liszewski MK, Kavanagh D, Fang CJ, Moulton E, Fremeaux-Bacchi V, et al. Implications of the initial mutations in membrane cofactor protein (MCP; CD46) leading to atypical hemolytic uremic syndrome. Mol Immunol. 2007;44:111\u201322.","journal-title":"Mol Immunol"},{"key":"4458_CR13","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1681\/ASN.2005101051","volume":"17","author":"V Fremeaux-Bacchi","year":"2006","unstructured":"Fremeaux-Bacchi V, Moulton EA, Kavanagh D, Dragon-Durey MA, Blouin J, Caudy A, et al. Genetic and functional analyses of membrane cofactor protein (CD46) mutations in atypical hemolytic uremic syndrome. J Am Soc Nephrol. 2006;17:2017\u201325.","journal-title":"J Am Soc Nephrol"},{"key":"4458_CR14","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.coi.2021.04.005","volume":"72","author":"MK Liszewski","year":"2021","unstructured":"Liszewski MK, Atkinson JP. Membrane cofactor protein (MCP; CD46): deficiency States and pathogen connections. Curr Opin Immunol. 2021;72:126\u201334.","journal-title":"Curr Opin Immunol"},{"key":"4458_CR15","doi-asserted-by":"publisher","first-page":"e2268","DOI":"10.1002\/mgg3.2268","volume":"11","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Bi S, Dai L, Zhao Y, Liu Y, Shi Z. Clinical report andgenetic analysis of a Chinese neonate with craniofacial microsomia caused by a splicingvariant of the splicing factor 3b subunit 2 gene. Mol Genet Genomic Med. 2023;11:e2268.","journal-title":"Mol Genet Genomic Med"},{"key":"4458_CR16","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41392-024-01734-2","volume":"9","author":"Y Tao","year":"2024","unstructured":"Tao Y, Zhang Q, Wang H, Yang X, Mu H. Alternative splicing and related RNA binding proteins in human health and disease. Signal Transduct Target Ther. 2024;9:26.","journal-title":"Signal Transduct Target Ther"},{"key":"4458_CR17","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American college of medical genetics and genomics and the association for molecular pathology. Genet Med. 2015;17:405\u201324.","journal-title":"Genet Med"},{"key":"4458_CR18","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1016\/S0140-6736(03)14742-3","volume":"362","author":"M Noris","year":"2003","unstructured":"Noris M, Brioschi S, Caprioli J, Todeschini M, Bresin E, Porrati F, et al. Familial haemolytic uraemic syndrome and an MCP mutation. Lancet. 2003;362:1542\u20137.","journal-title":"Lancet"},{"key":"4458_CR19","doi-asserted-by":"publisher","first-page":"2464","DOI":"10.4049\/jimmunol.1701695","volume":"200","author":"AJ Osborne","year":"2018","unstructured":"Osborne AJ, Breno M, Borsa NG, Bu F, Fr\u00e9meaux-Bacchi V, Gale DP, et al. Statistical validation of rare complement variants provides insights into the molecular basis of atypical hemolytic uremic syndrome and C3 glomerulopathy. J Immunol. 2018;200:2464\u201378.","journal-title":"J Immunol"},{"key":"4458_CR20","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.semnephrol.2013.08.003","volume":"33","author":"D Kavanagh","year":"2013","unstructured":"Kavanagh D, Goodship TH, Richards A. Atypical hemolytic uremic syndrome. Semin Nephrol. 2013;33:508\u201330.","journal-title":"Semin Nephrol"},{"key":"4458_CR21","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1007\/s10157-024-02505-7","volume":"28","author":"K Celegen","year":"2024","unstructured":"Celegen K, Gulhan B, Fidan K, Yuksel S, Yilmaz N, Y\u0131lmaz AC, et al. Adolescence-onset atypical hemolytic uremic syndrome: is it different from infant-onset? Clin Exp Nephrol. 2024;28:1027\u201337.","journal-title":"Clin Exp Nephrol"},{"key":"4458_CR22","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1016\/j.molimm.2006.08.024","volume":"44","author":"MK Liszewski","year":"2007","unstructured":"Liszewski MK, Leung MK, Schraml B, Goodship THJ, Atkinson JP. Modeling how CD46 deficiency predisposes to atypical hemolytic uremic syndrome. Mol Immunol. 2007;44:1559\u201368.","journal-title":"Mol Immunol"},{"key":"4458_CR23","doi-asserted-by":"publisher","first-page":"579418","DOI":"10.3389\/fmed.2020.579418","volume":"7","author":"R Piras","year":"2020","unstructured":"Piras R, Iatropoulos P, Bresin E, Todeschini M, Gastoldi S, Valoti E, et al. Molecular studies and an ex vivo complement assay on endothelium highlight the genetic complexity of atypical hemolytic uremic syndrome: the case of a pedigree with a null CD46 variant. Front Med (Lausanne). 2020;7:579418.","journal-title":"Front Med (Lausanne)"},{"key":"4458_CR24","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s12882-019-1314-1","volume":"20","author":"J Menne","year":"2019","unstructured":"Menne J, Delmas Y, Fakhouri F, Licht C, Lommel\u00e9 \u00c5, Minetti EE, et al. Outcomes in patients with atypical hemolytic uremic syndrome treated with Eculizumab in a long-term observational study. BMC Nephrol. 2019;20:125.","journal-title":"BMC Nephrol"},{"key":"4458_CR25","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1038\/ki.2014.423","volume":"87","author":"C Licht","year":"2015","unstructured":"Licht C, Greenbaum LA, Muus P, Babu S, Bedrosian CL, Cohen DJ, et al. Efficacy and safety of Eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies. Kidney Int. 2015;87:1061\u201373.","journal-title":"Kidney Int"},{"key":"4458_CR26","doi-asserted-by":"crossref","unstructured":"Vivarelli M, Barratt J, Beck LH Jr, Fakhouri F, Gale DP, Goicoechea de Jorge E, et al. The role of complement in kidney disease: conclusions from a kidney disease: improving global outcomes (KDIGO) controversies conference. Kidney Int. 2024;106:369\u201391.","DOI":"10.1016\/j.kint.2024.05.015"},{"key":"4458_CR27","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1007\/s00467-019-04233-7","volume":"34","author":"A Bagga","year":"2019","unstructured":"Bagga A, Khandelwal P, Mishra K, Thergaonkar R, Vasudevan A, Sharma J, et al. Hemolytic uremic syndrome in a developing country: consensus guidelines. Pediatr Nephrol. 2019;34:1465\u201382.","journal-title":"Pediatr Nephrol"},{"key":"4458_CR28","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1182\/blood-2005-10-007252","volume":"108","author":"J Caprioli","year":"2006","unstructured":"Caprioli J, Noris M, Brioschi S, Pianetti G, Castelletti F, Bettinaglio P, et al. Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood. 2006;108:1267\u201379.","journal-title":"Blood"},{"key":"4458_CR29","doi-asserted-by":"publisher","first-page":"2392","DOI":"10.1681\/ASN.2006080811","volume":"18","author":"AL Sellier-Leclerc","year":"2007","unstructured":"Sellier-Leclerc AL, Fremeaux-Bacchi V, Dragon-Durey MA, Macher MA, Niaudet P, Guest G, et al. Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome. J Am Soc Nephrol. 2007;18:2392\u2013400.","journal-title":"J Am Soc Nephrol"},{"key":"4458_CR30","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s00467-010-1556-4","volume":"26","author":"AM Waters","year":"2011","unstructured":"Waters AM, Licht C. aHUS caused by complement dysregulation: new therapies on the horizon. Pediatr Nephrol. 2011;26:41\u201357.","journal-title":"Pediatr Nephrol"},{"key":"4458_CR31","doi-asserted-by":"publisher","first-page":"100857","DOI":"10.1016\/j.trre.2024.100857","volume":"38","author":"S Obata","year":"2024","unstructured":"Obata S, Hullekes F, Riella LV, Cravedi P. Recurrent complement-mediated hemolytic uremic syndrome after kidney transplantation. Transpl Rev (Orlando). 2024;38:100857.","journal-title":"Transpl Rev (Orlando)"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-025-04458-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-025-04458-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-025-04458-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T11:05:01Z","timestamp":1758539101000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-025-04458-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,22]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4458"],"URL":"https:\/\/doi.org\/10.1186\/s12882-025-04458-9","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,22]]},"assertion":[{"value":"19 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was performed in accordance with the Declaration of Helsinki and was approved by the ethics committee of the Fuyang People\u2019s Hospital Affiliated with Anhui Medical University (Number: [2025]19), and all participants signed written informed consent forms. Clinical trial number: not applicable. The studies were conducted in accordance with local legislation and institutional requirements.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient and his parents for publication of this case report and accompanying images.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"516"}}